Physician

Revathi Angitapalli, M.D.

According to 2025 Medicare claims, Revathi Angitapalli, M.D. (NPI: 1497921829) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY CONSULTANTS PA (NPI: 1629021159; TIN: 752512142) and primary practice location at 76014-2084. Angitapalli is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Angitapalli's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 381 traditional Medicare patients, billed 176,527 HCPCS/CPT codes, and received $2,907,706 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,370 prescription claims across 318 beneficiaries totaling $4,099,566 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 15 claims. Open Payments data shows 134 records totaling $3,781. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $851,659 and ending at $2,907,706. Concurrently, Part D prescription costs have risen steadily, from $533,514 to $4,099,566. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	299	51,252	$851,659
2016	430	95,471	$1,579,135
2017	408	95,779	$3,027,468
2018	322	94,268	$2,254,443
2019	341	77,899	$1,242,308
2020	404	85,283	$1,206,435
2021	394	82,542	$1,324,148
2022	398	93,481	$1,416,493
2023	432	134,449	$2,173,236
2024	381	176,527	$2,907,706

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	125	623	$533,514
2016	180	903	$631,977
2017	267	1,282	$2,138,984
2018	277	1,495	$2,378,955
2019	272	1,528	$2,532,178
2020	281	1,355	$2,744,274
2021	249	1,158	$3,039,172
2022	170	688	$1,304,356
2023	229	840	$1,912,008
2024	318	1,370	$4,099,566

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	15	$626
2016	N/R	N/R	N/R
2017	N/R	11	$644
2018	N/R	N/R	N/R
2019	N/R	11	$2,539
2020	N/R	12	$1,679
2021	N/R	N/R	N/R
2022	N/R	15	$923
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	182	588	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	191	294	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	92	101	$63
71260	Ct scan of chest with contrast	49	64	$53
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	49	135	$46

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	39	1,022	$637,375
Xtandi	Enzalutamide	27	810	$410,801
Lenvima	Lenvatinib Mesylate	13	390	$316,086
Imbruvica	Ibrutinib	17	510	$255,554
Verzenio	Abemaciclib	16	448	$225,061

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	134	$3,781	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Revathi Angitapalli, M.D.?

Tedicare shows public-source Medicare data for Revathi Angitapalli, M.D. (NPI 1497921829), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Revathi Angitapalli, M.D. have ACO affiliation data?

Revathi Angitapalli, M.D. is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Revathi Angitapalli, M.D.?

Revathi Angitapalli, M.D. is linked to ONCOLOGY-HEMATOLOGY CONSULTANTS PA (billing NPI 1629021159) in the available physician profile data.

Does Revathi Angitapalli, M.D. have Open Payments data?

Revathi Angitapalli, M.D. has 134 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.